RATIO-MIRTAZAPINE TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

MIRTAZAPINE

Disponible desde:

RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED

Código ATC:

N06AX11

Designación común internacional (DCI):

MIRTAZAPINE

Dosis:

30MG

formulario farmacéutico:

TABLET

Composición:

MIRTAZAPINE 30MG

Vía de administración:

ORAL

Unidades en paquete:

100

tipo de receta:

Prescription

Área terapéutica:

MISCELLANEOUS ANTIDEPRESSANTS

Resumen del producto:

Active ingredient group (AIG) number: 0143928002; AHFS:

Estado de Autorización:

CANCELLED POST MARKET

Fecha de autorización:

2014-09-19

Ficha técnica

_Page 1 of 31_
PRODUCT MONOGRAPH
Pr
ratio-MIRTAZAPINE
30 mg tablets
Antidepressant
ratiopharm inc.
DATE OF PREPARATION:
17 800 rue Lapointe
August 26, 2005
Mirabel, PQ
J7J 1P3
Control #: 100745
_Page 2 of 31_
Table of Contents
PART I: HEALTH PROFESSIONAL
INFORMATION..............................................................3
SUMMARY PRODUCT
INFORMATION..............................................................................3
INDICATIONS AND CLINICAL
USE....................................................................................3
CONTRAINDICATIONS.........................................................................................................3
WARNINGS AND
PRECAUTIONS........................................................................................3
ADVERSE
REACTIONS.........................................................................................................7
DRUG
INTERACTIONS........................................................................................................12
DOSAGE AND
ADMINISTRATION....................................................................................13
OVERDOSAGE.......................................................................................................................14
ACTION AND CLINICAL
PHARMACOLOGY...................................................................14
STORAGE AND
STABILITY................................................................................................17
DOSAGE FORMS, COMPOSITION AND
PACKAGING...................................................17
PART II: SCIENTIFIC
INFORMATION......................................................................................18
PHARMACEUTICAL
INFORMATION................................................................................18
CLINICAL
TRIALS................................................................................................................20
DETAILED
PHARMACOLOGY........................................................................